Children of older fathers at increased risk of developing lymphoma
Is the threat having a child one day endure non-Hodgkin's lymphoma (NHL) another reason for older men to reconsider having more children? Previous studies have uncovered a link between men over 40 and an increased likelihood that the children they father either suffer from autism or schizophrenia compared to children fathered by men under 30, while other studies see a link between older fathers and their children developing breast or prostate cancer as adults.
Now a new and possibly unique study out of City of Hope Hospital in southern California suggests kids of born of older fathers are at an increased risk of developing NHLs.
Researchers looked at data on 110,999 California women. Those born to men over 40 years of age had a 59 percent greater risk of developing an NHL than those born to fathers younger than 25.
PUBLICATIONS
This study is being published online as well as in the June 15 issue of the American Journal of Epidemiology.
Source: City of Hope newsroom
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
